
Wockhardt’s Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance
Mumbai: Wockhardt announced that its novel intravenous antibiotic Foviscu® (WCK 4282) has successfully met the primary endpoint in a Phase 3 clinical trial in













